Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder.

CY-BOCS diagnostic test accuracy meta-analysis obsessive-compulsive disorder randomized controlled trials

Journal

Journal of the American Academy of Child and Adolescent Psychiatry
ISSN: 1527-5418
Titre abrégé: J Am Acad Child Adolesc Psychiatry
Pays: United States
ID NLM: 8704565

Informations de publication

Date de publication:
04 2022
Historique:
received: 16 11 2020
revised: 05 05 2021
accepted: 21 09 2021
pubmed: 2 10 2021
medline: 12 4 2022
entrez: 1 10 2021
Statut: ppublish

Résumé

A lack of universal definitions for response and remission in pediatric obsessive-compulsive disorder (OCD) has hampered the comparability of results across trials. To address this problem, we conducted an individual participant data diagnostic test accuracy meta-analysis to evaluate the discriminative ability of the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) in determining response and remission. We also aimed to generate empirically derived cutoffs on the CY-BOCS for these outcomes. A systematic review of PubMed, PsycINFO, Embase and CENTRAL identified 5,401 references; 42 randomized controlled clinical trials were considered eligible, and 21 provided data for inclusion (N = 1,234). Scores of ≤2 in the Clinical Global Impressions Improvement and Severity scales were chosen to define response and remission, respectively. A 2-stage, random-effects meta-analysis model was established. The area under the curve (AUC) and the Youden Index were computed to indicate the discriminative ability of the CY-BOCS and to guide for the optimal cutoff, respectively. The CY-BOCS had sufficient discriminative ability to determine response (AUC = 0.89) and remission (AUC = 0.92). The optimal cutoff for response was a ≥35% reduction from baseline to posttreatment (sensitivity = 83.9, 95% CI = 83.7-84.1; specificity = 81.7, 95% CI = 81.5-81.9). The optimal cutoff for remission was a posttreatment raw score of ≤12 (sensitivity = 82.0, 95% CI = 81.8-82.2; specificity = 84.6, 95% CI = 84.4-84.8). Meta-analysis identified empirically optimal cutoffs on the CY-BOCS to determine response and remission in pediatric OCD randomized controlled clinical trials. Systematic adoption of standardized operational definitions for response and remission will improve comparability across trials for pediatric OCD.

Identifiants

pubmed: 34597773
pii: S0890-8567(21)01843-8
doi: 10.1016/j.jaac.2021.05.027
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-507

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD084497
Pays : United States
Organisme : NIMH NIH HHS
ID : R42 MH123368
Pays : United States
Organisme : NIMH NIH HHS
ID : R61 MH121552
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH113250
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Luis C Farhat (LC)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Edoardo F Q Vattimo (EFQ)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Divya Ramakrishnan (D)

Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.

Jessica L S Levine (JLS)

Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.

Jessica A Johnson (JA)

Columbia University New York, New York; Columbia School of Nursing, New York.

Bekir B Artukoglu (BB)

SUNY Downstate Health Sciences University, New York.

Angeli Landeros-Weisenberger (A)

Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.

Fernando R Asbahr (FR)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Sandra L Cepeda (SL)

Baylor College of Medicine, Texas.

Jonathan S Comer (JS)

Center for Children and Families, Florida International University, Miami, Florida.

Daniel Fatori (D)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Martin E Franklin (ME)

University of Pennsylvania, Philadelphia; Rogers Memorial Hospital, Oconomowoc, Wisconsin.

Jennifer B Freeman (JB)

Warren Alpert Medical School, Brown University, Providence, Rhode Island.

Daniel A Geller (DA)

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Paul J Grant (PJ)

Washington, DC.

Wayne K Goodman (WK)

Baylor College of Medicine, Texas.

Isobel Heyman (I)

Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.

Tord Ivarsson (T)

Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Fabian Lenhard (F)

Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.

Adam B Lewin (AB)

University of South Florida, Hillsborough County.

Fenghua Li (F)

Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.

Lisa J Merlo (LJ)

University of Florida, Miami.

Hamid Mohsenabadi (H)

Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR.

Tara S Peris (TS)

Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles.

John Piacentini (J)

Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles.

Ana I Rosa-Alcázar (AI)

University of Murcia, Spain.

Àngel Rosa-Alcázar (À)

University of Murcia, Spain.

Michelle Rozenman (M)

University of Denver, Colorado.

Jeffrey J Sapyta (JJ)

Duke University School of Medicine, Durham, North Carolina.

Eva Serlachius (E)

Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.

Mohammad J Shabani (MJ)

Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR.

Roseli G Shavitt (RG)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Brent J Small (BJ)

School of Aging Studies, University of South Florida, Hillsborough County.

Gudmundur Skarphedinsson (G)

Faculty of Psychology, University of Iceland, Reykjavik.

Susan E Swedo (SE)

National Institutes of Health, Bethesda, Maryland.

Per Hove Thomsen (PH)

Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Aarhus University Hospital, Skejby, Denmark.

Cynthia Turner (C)

Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Bernhard Weidle (B)

Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olav's University Hospital, Trondheim, Norway.

Euripedes C Miguel (EC)

Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Eric A Storch (EA)

Baylor College of Medicine, Texas.

David Mataix-Cols (D)

Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.

Michael H Bloch (MH)

Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut. Electronic address: michael.bloch@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH